Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Autoimmune polyglandular syndrome and pulmonary arterial hypertension

F. J. García-Hernández, C. Ocaña-Medina, R. González-León, R. Garrido-Rasco, J. Sánchez-Román
European Respiratory Journal 2006 27: 657; DOI: 10.1183/09031936.06.00133505
F. J. García-Hernández
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Ocaña-Medina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. González-León
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Garrido-Rasco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Sánchez-Román
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

Pulmonary arterial hypertension (PAH) is a serious disease. New treatments have favourably changed the prognosis. Its frequent association with autoimmune thyroid disease (ATD) has been previously acknowledged 1–3. ATD may also be associated with other autoimmune diseases. Here, we report two cases of PAH associated with type II autoimmune polyglandular syndrome (APS).

In the first case, a 50-yr-old female was diagnosed with idiopathic PAH (dyspnoea on exertion, angina, and mean pulmonary arterial pressure (mPAP) determined by right catheterisation 6.38 kPa (48 mmHg)). Slightly high levels of thyrotropin (TSH) were detected, with normal free thyroxine (FT4) levels, and high serum concentrations of anti-thyroglobulin and anti-thyroid peroxidase antibodies. She improved with i.v. epoprostenol, although it was later necessary to add sildenafil and bosentan. In October 2003, a goitre appeared. Levels of TSH and FT4 were normal. Scintigraphy showed a diffuse goitre without changes in the tracer uptake. Data were concordant with chronic thyroiditis. In August 2004, she presented with polyuria and polydipsia and was admitted to Virgen del Rocío University Hospital (Seville, Spain) with severe hyperglycaemia. She was diagnosed with diabetic ketoacidosis and progressed favourably after treatment with insulin. Pancreatic islet-cell antibodies (ICA) were positive. The scope of the immunological and endocrinological studies was broadened, with the following results: positive anti-adrenal, anti-ovarian, anti-gliadin, anti-endomysial and anti-intrinsic factor antibodies, without adrenal insufficiency, ovarian disfunction, malabsorption or vitamin B12 deficiency.

In the second case, a 31-yr-old female, with a history of smoking and previous treatment with oral contraceptives, presented with asthenia, cold intolerance, dyspnoea on exertion and oedemas. She was diagnosed with hypothyroidism as a result of ATD and improved after treatment with levothyroxine. Nevertheless, the oedemas remained, dyspnoea progressed and the patient became icteric due to stasis liver. Echocardiography revealed PAH, confirmed by right catheterisation (mPAP 9.70 kPa (73 mmHg)). Secondary PAH causes were ruled out. Pernicious anaemia was diagnosed with macrocytic anaemia, low vitamin B12 and normal folic acid levels, positive anti-gastric parietal cell antibodies, characteristic changes in the Schilling test, and normal results for malabsorption study with negative anti-gliadin and anti-endomysial antibodies. Treatment with i.v. epoprostenol, anticoagulants and vitamin B12 was initiated. Subsequently, the patient was also given sidenafil followed by bosentan, due to therapeutic failure. Epoprostenol was substituted by subcutaneous treprostinil because of repeated losses of vascular access. Due to the association between ATD and pernicious anaemia, the scope of the immunological and endocrinological studies was broadened with the following results: positive anti-adrenal, ICA and anti-ovarian antibodies, without adrenal insufficiency, diabetes or ovarian dysfunction.

APS is defined by the association of several autoimmune diseases, which are not always endocrinological in nature. There are several clinical forms, all with a genetic basis. Type I APS normally begins in childhood and is characterised by chronic mucotaneous candidiasis, hypoparathyroidism and adrenal insufficiency. It is an autosomal recessive inherited disorder, caused by mutations in the autoimmune regulator gene. These mutations determine the risk for the development of multiple autoimmune disorders (type I diabetes, ATD, alopecia, vitiligo, pernicious anaemia, ovarian atrophy, etc.). Type II APS is classically associated with adrenal insufficiency, ATD and type I diabetes, although its range of clinical manifestations varies substantially. Some authors distinguish a type III APS, which would link ATD to other autoimmune organ-specific diseases (but not adrenal insufficiency or diabetes), such as pernicious anaemia, while others believe it to be a mere variant of type II APS 4. The association between PAH and APS has been previously described. Korniszewski et al. 5 and Bhansali et al. 6 found type I APS in both cases, and Barrou et al. 7 type II APS, in a patient with early ovarian failure, renal insufficiency, ATD and positive anti-gastric parietal cell antibodies without pernicious anaemia. Using a PubMed database search, using the descriptions “pulmonary hypertension” and “autoimmune polyglandular syndrome” between 1980 and 2005, we have not found any more described cases of PAH associated with type II APS. All of these authors suggest the participation of autoimmune mechanisms in the development of PAH. This is also supported by the frequency of PAH in patients with connective tissue diseases.

The cases which we have described provide more arguments regarding a possible link between autoimmune polyglandular syndrome and pulmonary arterial hypertension. We are unaware if a possible pathogenic link could exist between them, such as a common genetic basis or shared autoimmune mechanisms.

    • © ERS Journals Ltd

    References

    1. ↵
      Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002;122:1668–1673.
      OpenUrlCrossRefPubMedWeb of Science
    2. Curnock AL, Dweik RA, Higgins BH, Saadi HF, Arroliga AC. High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci 1999;318:289–292.
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      García Hernández FJ, Ocaña Medina C, Mateos Romero L, et al. Combined treatment with intravenous prostacyclin and sildenafil in patients with pulmonary hypertension: report of 4 cases. Med Clin (Barc) 2004;122:64–66.
      OpenUrlPubMed
    4. ↵
      Eisenbarth GS, Gorrlieb PA. Medical progress: autoimmune polyendocrine syndromes. N Engl J Med 2004;350:2068–2079.
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      Korniszewski L, Kurzyna M, Stolarski B, Torbicki A, Smerdel A, Ploski R. Fatal primary pulmonary hypertension in a 30-yr-old female with APECED syndrome. Eur Respir J 2003;22:709–711.
      OpenUrlAbstract/FREE Full Text
    6. ↵
      Bhansali A, Kotwal N, Suresh V, Murlidharan R, Chattopadhyay A, Mathur K. Polyglandular autoimmune syndrome type 1 without chronic mucocutaneous candidiasis in a 16 year-old male. J Pediatr Endocrinol Metab 2003;16:103–105.
      OpenUrlPubMed
    7. ↵
      Barrou Z, Pehuet-Figoni M, Weber S, Lockhart A, Luton JP. Polyendocrinopathy combined with primary pulmonary arterial hypertension. Presse Med 1989;18:963–965.
      OpenUrlPubMed
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 27 Issue 3 Table of Contents
    European Respiratory Journal: 27 (3)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Autoimmune polyglandular syndrome and pulmonary arterial hypertension
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Autoimmune polyglandular syndrome and pulmonary arterial hypertension
    F. J. García-Hernández, C. Ocaña-Medina, R. González-León, R. Garrido-Rasco, J. Sánchez-Román
    European Respiratory Journal Mar 2006, 27 (3) 657; DOI: 10.1183/09031936.06.00133505

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Autoimmune polyglandular syndrome and pulmonary arterial hypertension
    F. J. García-Hernández, C. Ocaña-Medina, R. González-León, R. Garrido-Rasco, J. Sánchez-Román
    European Respiratory Journal Mar 2006, 27 (3) 657; DOI: 10.1183/09031936.06.00133505
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Latent COPD: a proposed new term in the disease nomenclature
    • Empiric anti-anaerobic antibiotics are associated with adverse clinical outcomes
    • Anti-anaerobic antibiotics: indication is key
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society